Hiroaki Naritomi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiroaki Naritomi has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Derk Wolfgang Krieger
Stroke Unit, Mediclinic City Hospital , Building 37–26th St, Dubai
1 shared publication H Moriwaki
Cerebrovascular Division, Department of Internal Medicine, National Cardiovascular Centre, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan
1 shared publicationH Oe
Cerebrovascular Division, Department of Internal Medicine, National Cardiovascular Centre, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan
1 shared publication- Haruhiko Hoshino
Department of Neurology, Tokyo Saiseikai Central Hospital, Tokyo, Japan
1 shared publication Heizo Tanaka
Koshien University, Takarazuka, Japan
1 shared publicationHidekazu Tomimoto
Department of Neurology, Graduate School of Medicine, Mie University, Tsu, Japan (H.T.).
1 shared publication
Latest Publications
- 1 March 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (3) , 697-705
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial
Background: The effectiveness of long-term dual antiplatelet therapy (DAPT) to prevent recurrent strokes in patients with lacunar stroke remains unclarified. Therefore, this study aimed to compare and to elucidate the safety and effectiveness of DAPT and single antiplatelet therapy (SAPT) in preventing recurrence in chronic lacunar stroke. Methods: CSPS.com (Cilostazol Stroke Prevention Study for Antiplatelet Combination) was a prospective, multicenter, randomized controlled trial. In this prespecified subanalysis, 925 patients (mean age, 69.5 years; 69.4% men) with lacunar stroke were selected from 1884 patients with high-risk noncardioembolic stroke, enrolled in the CSPS.com trial after 8 to 180 days following stroke. Patients were randomly assigned to receive either SAPT or DAPT using cilostazol and were followed for 0.5 to 3.5 years. The primary efficacy outcome was the first recurrence of ischemic stroke. The safety outcomes were severe or life-threatening bleeding. Results: The DAPT group receiving cilostazol and either aspirin or clopidogrel and SAPT group receiving aspirin or clopidogrel alone comprised 464 (50.2%) and 461 (49.8%) patients, respectively. Ischemic stroke occurred in 12 of 464 patients (1.84 per 100 patient-years) in the DAPT group and 31 of 461 patients (4.42 per 100 patient-years) in the SAPT group, during follow-up. After adjusting for multiple potential confounding factors, ischemic stroke risk was significantly lower in the DAPT group than in the SAPT group (hazard ratio, 0.43 [95% CI, 0.22–0.84]). The rate of severe or life-threatening hemorrhage did not differ significantly between the groups (2 patients [0.31 per 100 patient-years] versus 6 patients [0.86 per 100 patient-years] in the DAPT and SAPT groups, respectively; hazard ratio, 0.36 [95% CI, 0.07–1.81]). Conclusions: In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01995370. URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000012180.
- 1 March 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (3) , 697-705
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial
Background: The effectiveness of long-term dual antiplatelet therapy (DAPT) to prevent recurrent strokes in patients with lacunar stroke remains unclarified. Therefore, this study aimed to compare and to elucidate the safety and effectiveness of DAPT and single antiplatelet therapy (SAPT) in preventing recurrence in chronic lacunar stroke. Methods: CSPS.com (Cilostazol Stroke Prevention Study for Antiplatelet Combination) was a prospective, multicenter, randomized controlled trial. In this prespecified subanalysis, 925 patients (mean age, 69.5 years; 69.4% men) with lacunar stroke were selected from 1884 patients with high-risk noncardioembolic stroke, enrolled in the CSPS.com trial after 8 to 180 days following stroke. Patients were randomly assigned to receive either SAPT or DAPT using cilostazol and were followed for 0.5 to 3.5 years. The primary efficacy outcome was the first recurrence of ischemic stroke. The safety outcomes were severe or life-threatening bleeding. Results: The DAPT group receiving cilostazol and either aspirin or clopidogrel and SAPT group receiving aspirin or clopidogrel alone comprised 464 (50.2%) and 461 (49.8%) patients, respectively. Ischemic stroke occurred in 12 of 464 patients (1.84 per 100 patient-years) in the DAPT group and 31 of 461 patients (4.42 per 100 patient-years) in the SAPT group, during follow-up. After adjusting for multiple potential confounding factors, ischemic stroke risk was significantly lower in the DAPT group than in the SAPT group (hazard ratio, 0.43 [95% CI, 0.22–0.84]). The rate of severe or life-threatening hemorrhage did not differ significantly between the groups (2 patients [0.31 per 100 patient-years] versus 6 patients [0.86 per 100 patient-years] in the DAPT and SAPT groups, respectively; hazard ratio, 0.36 [95% CI, 0.07–1.81]). Conclusions: In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01995370. URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000012180.
- Open Access
- 1 January 2018
- Published by Society of Physical Therapy Science in Rigakuryoho Kagaku
- Vol. 33 (2) , 323-326
Reference Values of Outdoor Activities of Stroke Patients Discharged to Home: Investigation of Physical Factors at Discharge
- 1 January 2018
- Published by Society of Physical Therapy Science in Rigakuryoho Kagaku
- Vol. 33 (2) , 323-326
Open AccessReference Values of Outdoor Activities of Stroke Patients Discharged to Home: Investigation of Physical Factors at Discharge
- Open Access
- 8 July 2013
- Published by S. Karger AG
- Vol. 32, 45-53
Compensatory Contribution of the Contralateral Pyramidal Tract after Stroke
Stroke is a leading cause of long-term disability with early accelerated followed by gradual recovery during the first 6 months after the ictus. The most important mechanism concerning early recovery is thought to be brain plasticity provided by anatomical and functional reorganization of the central nervous system after injury. Recent advances in noninvasive, functional brain imaging techniques provided some insight indicating the contribution of ipsilateral uncrossed corticospinal tracts in motor recovery after stroke. Since motor tracts vary considerably among subjects, the ratio of contralateral corticospinal tract fibers and their interhemispheric control versus the amount and function of ipsilateral corticospinal tract fibers may affect the scale of motor recovery after stroke. Further studies are needed to clarify the mechanisms of motor recovery after stroke in humans.
- 8 July 2013
- Published by S. Karger AG
- Vol. 32, 45-53
Open AccessCompensatory Contribution of the Contralateral Pyramidal Tract after Stroke
Stroke is a leading cause of long-term disability with early accelerated followed by gradual recovery during the first 6 months after the ictus. The most important mechanism concerning early recovery is thought to be brain plasticity provided by anatomical and functional reorganization of the central nervous system after injury. Recent advances in noninvasive, functional brain imaging techniques provided some insight indicating the contribution of ipsilateral uncrossed corticospinal tracts in motor recovery after stroke. Since motor tracts vary considerably among subjects, the ratio of contralateral corticospinal tract fibers and their interhemispheric control versus the amount and function of ipsilateral corticospinal tract fibers may affect the scale of motor recovery after stroke. Further studies are needed to clarify the mechanisms of motor recovery after stroke in humans.
- 18 December 2009
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 29 (3) , 221-227
Symptom Progression or Fluctuation in Transient Ischemic Attack Patients Predicts Subsequent Stroke
Background: The aim of this study was to investigate whether progression or fluctuation of transient ischemic attack (TIA) symptoms is a predictor of subsequent stroke. Methods: We prospectively analyzed 113 consecutive patients admitted with a diagnosis of classical TIA with symptom duration of less than 24 h. We assessed the background characteristics, TIA symptoms, attack characteristics, results of in-hospital examinations, and prescription of antithrombotic agents on discharge for each patient. We then analyzed the factors related to progression or fluctuation of TIA symptoms. Results: Of the 113 patients, 35 (31.0%) exhibited symptom progression or fluctuation. Subsequent stroke occurred in 12 (10.6%) patients within 180 days. Symptom progression or fluctuation was significantly related to the TIA symptoms of speech disturbance, hemiparesis, and monoparesis, and were also related to subsequent stroke occurrence within 90 days (29 vs. 3%, p = 0.004) and 180 days (23 vs. 5%, p = 0.008). In a logistic regression model analysis, symptom progression or fluctuation was a significant predictor of subsequent stroke within 90 days (odds ratio = 7.65, 95% CI 1.27–46.06) and 180 days (odds ratio = 4.44, 95% CI 1.08–18.13), independently of other predictors demonstrated in previous studies. Conclusions: Progression or fluctuation of TIA symptoms may be an important predictor of subsequent stroke. A detailed interview about the characteristics of each attack is also indispensable for the provision of appropriate care to TIA patients.
- 18 December 2009
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 29 (3) , 221-227
Symptom Progression or Fluctuation in Transient Ischemic Attack Patients Predicts Subsequent Stroke
Background: The aim of this study was to investigate whether progression or fluctuation of transient ischemic attack (TIA) symptoms is a predictor of subsequent stroke. Methods: We prospectively analyzed 113 consecutive patients admitted with a diagnosis of classical TIA with symptom duration of less than 24 h. We assessed the background characteristics, TIA symptoms, attack characteristics, results of in-hospital examinations, and prescription of antithrombotic agents on discharge for each patient. We then analyzed the factors related to progression or fluctuation of TIA symptoms. Results: Of the 113 patients, 35 (31.0%) exhibited symptom progression or fluctuation. Subsequent stroke occurred in 12 (10.6%) patients within 180 days. Symptom progression or fluctuation was significantly related to the TIA symptoms of speech disturbance, hemiparesis, and monoparesis, and were also related to subsequent stroke occurrence within 90 days (29 vs. 3%, p = 0.004) and 180 days (23 vs. 5%, p = 0.008). In a logistic regression model analysis, symptom progression or fluctuation was a significant predictor of subsequent stroke within 90 days (odds ratio = 7.65, 95% CI 1.27–46.06) and 180 days (odds ratio = 4.44, 95% CI 1.08–18.13), independently of other predictors demonstrated in previous studies. Conclusions: Progression or fluctuation of TIA symptoms may be an important predictor of subsequent stroke. A detailed interview about the characteristics of each attack is also indispensable for the provision of appropriate care to TIA patients.
- Open Access
- 1 January 2008
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 31 (2) , 295-304
Efficacy and Safety of Long-Term Losartan Therapy Demonstrated by a Prospective Observational Study in Japanese Patients with Hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) Study
The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicentered, observational study that was designed to enroll 30,000 hypertensive Japanese patients from more than 3,000 private practitioners. It is the first large-scale observational study to assess the efficacy and safety of losartan, an angiotensin II receptor antagonist, in Japan. Patients were enrolled between June 2000 and May 2002, and followed up to June 2005. The data from 29,850 patients were used for the analysis of safety and efficacy. These patients were treated with losartan mostly at a daily dose of 25–50 mg. The mean follow-up period was 2.9 years. The patients were aged 62.4±12.1 years (mean±SD) and their mean systolic/diastolic blood pressure was 165.3±17.2/94.3±11.7 mmHg (mean±SD). Mean blood pressure in patients who were evaluated for efficacy decreased from 165.8/94.8 mmHg (n=26,512) at baseline to 145.5/84.4 mmHg after 3 months (n=21,269) and 138.6/80.0 mmHg after 36 months of treatment (n=13,879). Blood pressure was well controlled during the study period by losartan alone or losartan-based combination therapy. In nearly half of the patients, blood pressure was reduced to less than 140/90 mmHg during the study period. In addition to its antihypertensive effect, losartan reduced the uric acid level in patients whose baseline uric acid level was ≥7 mg/dL. Losartan also prevented acceleration of proteinuria. Adverse drug reactions occurred in 1,081 of the 29,850 patients. Long-term losartan therapy was effective and well tolerated in Japanese clinical practice.
- 1 January 2008
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 31 (2) , 295-304
Open AccessEfficacy and Safety of Long-Term Losartan Therapy Demonstrated by a Prospective Observational Study in Japanese Patients with Hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) Study
The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicentered, observational study that was designed to enroll 30,000 hypertensive Japanese patients from more than 3,000 private practitioners. It is the first large-scale observational study to assess the efficacy and safety of losartan, an angiotensin II receptor antagonist, in Japan. Patients were enrolled between June 2000 and May 2002, and followed up to June 2005. The data from 29,850 patients were used for the analysis of safety and efficacy. These patients were treated with losartan mostly at a daily dose of 25–50 mg. The mean follow-up period was 2.9 years. The patients were aged 62.4±12.1 years (mean±SD) and their mean systolic/diastolic blood pressure was 165.3±17.2/94.3±11.7 mmHg (mean±SD). Mean blood pressure in patients who were evaluated for efficacy decreased from 165.8/94.8 mmHg (n=26,512) at baseline to 145.5/84.4 mmHg after 3 months (n=21,269) and 138.6/80.0 mmHg after 36 months of treatment (n=13,879). Blood pressure was well controlled during the study period by losartan alone or losartan-based combination therapy. In nearly half of the patients, blood pressure was reduced to less than 140/90 mmHg during the study period. In addition to its antihypertensive effect, losartan reduced the uric acid level in patients whose baseline uric acid level was ≥7 mg/dL. Losartan also prevented acceleration of proteinuria. Adverse drug reactions occurred in 1,081 of the 29,850 patients. Long-term losartan therapy was effective and well tolerated in Japanese clinical practice.
- Open Access
- 1 May 2003
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 74 (5) , 689-690
Association of cardiomyopathy caused by autonomic nervous system impairment with the Miller Fisher syndrome
A 58 year old man was admitted to our hospital because of ataxia, ophthalmoplegia, and dysarthria. He had a 10 year history of hypertension. Four weeks before admission, he had common-cold-like symptoms. Ten days before admission, he developed difficulties with walking and speaking. The next day he was unable to walk or lift his eyelids. He was admitted to another hospital, where he was diagnosed as having a brain stem infarct. During admission, he developed tightness in the chest for three to four days which improved spontaneously. Because of exacerbation of his neurological symptoms, he was transferred to our hospital.
- 1 May 2003
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 74 (5) , 689-690
Open AccessAssociation of cardiomyopathy caused by autonomic nervous system impairment with the Miller Fisher syndrome
A 58 year old man was admitted to our hospital because of ataxia, ophthalmoplegia, and dysarthria. He had a 10 year history of hypertension. Four weeks before admission, he had common-cold-like symptoms. Ten days before admission, he developed difficulties with walking and speaking. The next day he was unable to walk or lift his eyelids. He was admitted to another hospital, where he was diagnosed as having a brain stem infarct. During admission, he developed tightness in the chest for three to four days which improved spontaneously. Because of exacerbation of his neurological symptoms, he was transferred to our hospital.
- 20 August 1993
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 3 (4) , 206-212
Infarction in the Anterior Inferior Cerebellar Artery Territory: Magnetic Resonance Imaging and Auditory Brain Stem Responses
Infarction in the anterior inferior cerebellar artery (AICA) territory is rare, and most reports on such infarction have been restricted to autopsy studies. We analyzed the clinical figures of 5 patients with AICA territory infarction diagnosed by magnetic resonance imaging (MRI). They all developed dizziness or vertigo, unilateral ataxia and homolateral hearing impairment. The MRI demonstrated ischemic lesions in the ipsilateral middle cerebellar peduncle. All patients showed excellent neurological recovery and were ambulatory at discharge. In our series, unilateral hearing impairment was the most crucial sign for diagnosis of the AICA syndrome. Results for the auditory brain stem response suggested that the hearing impairment may be partly attributable to chochlear ischemia.
- 20 August 1993
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 3 (4) , 206-212
Infarction in the Anterior Inferior Cerebellar Artery Territory: Magnetic Resonance Imaging and Auditory Brain Stem Responses
Infarction in the anterior inferior cerebellar artery (AICA) territory is rare, and most reports on such infarction have been restricted to autopsy studies. We analyzed the clinical figures of 5 patients with AICA territory infarction diagnosed by magnetic resonance imaging (MRI). They all developed dizziness or vertigo, unilateral ataxia and homolateral hearing impairment. The MRI demonstrated ischemic lesions in the ipsilateral middle cerebellar peduncle. All patients showed excellent neurological recovery and were ambulatory at discharge. In our series, unilateral hearing impairment was the most crucial sign for diagnosis of the AICA syndrome. Results for the auditory brain stem response suggested that the hearing impairment may be partly attributable to chochlear ischemia.